Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (Diluted Average): 2012-2025

Historic Shares Outstanding (Diluted Average) for Enanta Pharmaceuticals (ENTA) over the last 4 years, with Sep 2025 value amounting to $21,336.

  • Enanta Pharmaceuticals' Shares Outstanding (Diluted Average) rose 0.85% to $21,336 in Q3 2025 from the same period last year, while for Sep 2025 it was $21,336, marking a year-over-year increase of 0.85%. This contributed to the annual value of $21,336 for FY2025, which is 0.85% up from last year.
  • Enanta Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $21,336 in Q3 2025, which was down 99.90% from $21.4 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $21.4 million during Q2 2025, with a 5-year trough of $20,171 in Q3 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $15.4 million, with a median of $21.1 million in 2023.
  • Data for Enanta Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 2.36% (in 2023) over the last 5 years.
  • Enanta Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $20.4 million in 2021, then increased by 2.10% to $20.8 million in 2022, then grew by 1.31% to $21.1 million in 2023, then rose by 0.71% to $21.2 million in 2024, then rose by 0.85% to $21,336 in 2025.
  • Its last three reported values are $21,336 in Q3 2025, $21.4 million for Q2 2025, and $21.4 million during Q1 2025.